Asia Pacific Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases,

Asia Pacific Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

The Asia Pacific monoclonal antibodies market is expected to reach US$ 44,729.7 million by 2028 from US$ 18,344.5 million in 2021. The market is estimated to grow at a CAGR of 13.6% from 2021-2028.

Advancements in manufacturing technologies with packaging and delivery can lower m AB production costs and increase efficiency. For example, WHO policy guidelines play an important role in adopting new technologies and their integration in financing and procurement platforms. Therefore, novel technologies are expected to lower m AB development and manufacturing costs during the forecast period. For instance, the IAVI report states that many researchers are applying cost-effective technologies for optimizing HIV-specific bnm ABs for increasing potency, thereby lowering the cost of the overall product. Additionally, recent technological advancements offer lucrative opportunities to quickly isolate, develop and produce therapeutic or preventative m ABs as a complementary approach to vaccine development as part of preparing for or responding to current and future pandemic outbreaks. For example, incorporating technological advancements in the process of identifying, optimizing, and producing results in delivering more potent, lower-cost monoclonal antibody products. Together, such strategic actions are expected to make it possible to address the growing inequity to these products, saving or improving millions of lives in the process in the near future. Therefore, with the influx of advanced technology for the development of m ABs, the m AB market will grow faster in the coming years. For example, as per the statistics released by Firestone, approx. 43% of m AB sales were intended to treat immune system diseases, while 35% were used for tumor therapy in 2015. The sales of m ABs accounted for over half of the total sales of all biopharmaceutical products.

The supply chain disruptions, along with the massive demand for efficient treatments for the therapy of COVID-19, have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected that economies in the Asia Pacific region. Countries such as India, China, Japan, South Korea were adversely affected by the pandemic. The socio-economics were severely affected, rising in negative inflation, GDPs, and a surge in unemployment in the region. The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths. Manufacturers and suppliers of pharmaceuticals shift their focus from regular OTC and prescription drugs to developing and supplying COVID-19 essentials and medical devices used for respiratory issues. This scenario negatively impacts the monoclonal antibody. This pandemic is affecting the business operation of the various key players operating in this region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Asia Pacific monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Monoclonal Antibodies Market Segmentation By Source

Human Humanized Chimeric Murine By Production Method

In-Vitro In-Vivo By Indication

Cancer Autoimmune Diseases Infectious Diseases Inflammatory Diseases Microbial Diseases Others By Application

Therapeutic Applications Diagnostic Applications Research Applications By End-User

Hospitals Research Institutes Others By Country

Asia Pacific China Japan India South Korea Australia Rest of Asia Pacific Companies Mentioned

Novartis AG Pfizer Inc. Glaxo Smith Kline plc. Amgen Inc DAIICHI SANKYO COMPANY, LIMITED F. Hoffmann-La Roche Ltd. Astra Zeneca Eli Lilly and Company Bayer AG Bristol-Myers Squibb Company

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific monoclonal antibodies market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.